312 related articles for article (PubMed ID: 28106545)
21. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR; Hutson PR; Havighurst TC; Cleary JF
Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant aromatase inhibitor therapy in patients with stage I breast cancer at a regional oncology center in Israel: implementation of a 'switching' policy in postmenopausal patients after initial tamoxifen.
Geffen DB; Tokar M; Abu-Ghanem S; Braunstein R; Koretz M; Amir N; Delgado B; Sion-Vardi N; Ariad S; Lazarev I
Oncology; 2013; 85(3):145-52. PubMed ID: 23988814
[TBL] [Abstract][Full Text] [Related]
23. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
24. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
[TBL] [Abstract][Full Text] [Related]
25. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
26. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
Spicer J; Ellis P
Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
[TBL] [Abstract][Full Text] [Related]
27. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
28. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
Gligorov J; Pritchard K; Goss P
Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
[TBL] [Abstract][Full Text] [Related]
30. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
Van Asten K; Poppe A; Punie K; Jongen L; Lintermans A; Wildiers H; Neven P
Curr Treat Options Oncol; 2015 Jul; 16(7):31. PubMed ID: 26031545
[TBL] [Abstract][Full Text] [Related]
31. Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy.
Arpino G; De Angelis C; Buono G; Colao A; Giuliano M; Malgieri S; Cicala S; De Laurentiis M; Accurso A; Crispo A; Limite G; Lauria R; Veneziani BM; Forestieri V; Bruzzese D; De Placido S
Breast Cancer Res Treat; 2015 Nov; 154(1):127-32. PubMed ID: 26424165
[TBL] [Abstract][Full Text] [Related]
32. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
[TBL] [Abstract][Full Text] [Related]
33. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
34. A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
Garrone O; Bertelli G; Principe E; Lewis PD; Occelli M; Miraglio E; Merlano MC
Tumori; 2014; 100(6):620-4. PubMed ID: 25688495
[TBL] [Abstract][Full Text] [Related]
35. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant hormonal therapy in perimenopausal patients.
Pinto Marín A; Ballesteros García AI; Izarzugaza Perón Y; Mansó Sánchez L; López-Tarruella Cobo S; Zamora Auñón P
Adv Ther; 2011 Sep; 28 Suppl 6():39-49. PubMed ID: 21922394
[TBL] [Abstract][Full Text] [Related]
37. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
38. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
[TBL] [Abstract][Full Text] [Related]
39. [Current adjuvant endocrine treatment of breast cancer].
Dedes KJ; Gabriel N; Fink D
Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
[TBL] [Abstract][Full Text] [Related]
40. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
Santa-Maria CA; Blackford A; Nguyen AT; Skaar TC; Philips S; Oesterreich S; Rae JM; Desta Z; Robarge J; Henry NL; Storniolo AM; Hayes DF; Blumenthal RS; Ouyang P; Post WS; Flockhart DA; Stearns V;
Clin Cancer Res; 2016 Mar; 22(6):1395-402. PubMed ID: 26463708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
